

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  23D0371400	<b>(X3) Date Survey Completed</b>  08/27/2018
<b>Name of Provider or Supplier</b>  Mahmoud Al-Hadidi Md	<b>Street Address, City, State</b>  27550 Hoover, Warren, MI	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: . Based on review of the CMS database and review of the American Association of Bioanalysts (AAB) final proficiency testing reports, it was determined the laboratory failed to successfully participate in a CMS approved proficiency testing program for the hematology analyte hematocrit (HCT) . Findings include: Review of the CMS database and the AAB final proficiency testing reports showed unsatisfactory performance for two consecutive proficiency testing events for the hematology analyte: HCT. Refer to D2130.</p>
<b>D2130</b>	<b>HEMATOLOGY</b>

CFR(s): 493.851(f)

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

. Based on review of the CMS database and review of the American Association of Bioanalysts final proficiency testing reports, the laboratory failed to achieve satisfactory performance for the hematology analyte hematocrit (HCT) in two consecutive testing events. Findings include: Unsatisfactory performance for two consecutive PT events constituting unsuccessful performance for hematocrit: HCT PT Event Score 3rd event 2017 20% 1st event 2018 20%